Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

109.72 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
63 64 Next >
Smart Money Is Betting Big In NVO Options
Via Benzinga
Diabetes Drug Made For Under $5 Costs Americans $1,000, Drawing Comparisons To Martin Shrikeli While Juicing Profits for A Drug Giant
Via Benzinga
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
Could Viking Therapeutics Stock Be a Millionaire Maker?
There is a plausible path for this biotech stock to make some investors millionaires. 
Via The Motley Fool
Is It Too Late to Buy Eli Lilly Stock?
There's more to the Lilly story than just excellence in one treatment area. 
Via The Motley Fool
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
How Is The Market Feeling About Novo Nordisk?
Via Benzinga
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations. 
Via The Motley Fool
Is Novo Nordisk the Best Healthcare Stock for You?
Novo Nordisk has been a hot buy in recent years, but in the long run, the stock can still go a whole lot higher. 
Via The Motley Fool
2 Top Biotech Buyout Candidates
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... 
Via Talk Markets
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
The semaglutide maker just announced a strategic acquisition that will be a green flag for its future value. 
Via The Motley Fool
Bernie Sanders Slams 'Outrageous' Prices Of Miracle Weight Loss Drug Ozempic, Mulls Meeting With Novo Nordisk CEO
Sen. Bernie Sanders has taken a stand against the "outrageous" prices of diabetes drug Ozempic by Novo Nordisk. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bitcoin Vs. Gold Vs. SPY: Which Asset Class Would've Given Best Returns On $1000 Investment In Q1?
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried about the sustainability of the uptrend. 
Via Benzinga
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Knocking on the Trillion-Dollar Door: 3 Stocks Ready to Shatter the Market Cap Milestone
The trillion-dollar market cap club could fill with some high-momentum large-caps that could give the Magnificent Seven a good run. 
Via InvestorPlace
How Much Does It Cost To Make Novo Nordisk's Ozempic? Shockingly Low Against $1,000 Price Tag, Study Shows
Study reveals stark contrast: Novo Nordisk's Ozempic diabetes drug costs nearly $1,000 monthly in the U.S., yet could be produced for less than $5. This underscores the affordability challenge faced by... 
Via Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break. 
Via Investor's Business Daily
Insurance Coverage For Weight Loss Drugs - Elevance, CVS Health Become First To Extend Coverage To Novo Nordisk's Successful Wegovy For Certain Patients
Major U.S. health insurers CVS Health, Elevance Health, and Kaiser Permanente now reimburse for Novo Nordisk's Wegovy for specific Medicare individuals with heart-related conditions. This shift aims to... 
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
3 Healthcare Stocks to Buy From 3 of the Best Actively Managed Funds
Although the performance of these three healthcare stocks has been inconsistent in 2024, they remain undervalued. 
Via InvestorPlace
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
Prediction: This Will Be the Next "Magnificent Seven" Stock
This particular company's growth is set to take off... 
Via The Motley Fool
The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months
Let's review what Wall Street analysts believe are potentially the stocks to double over the next 12 months. 
Via InvestorPlace
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand. 
Via Benzinga
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its... 
Via Benzinga
3 Stocks to Buy for the Next Bull Run: March 2024
Look for these stocks to buy to continue moving higher in coming quarters propelled by multiple catalysts and strong earnings. 
Via InvestorPlace
Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?
Their joint project is cutting-edge, but it won't pay off immediately. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.